1.
Journal of Leukemia & Lymphoma
;
(12): 311-314, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-475703
ABSTRACT
Allogeneic stem cell transplantation (allo-HSCT) is probably the only treatment for multiple myeloma (MM) with a curative potential.However,the application of allo-HSCT is limited by the high transplant-related mortality (TRM).Although the introduction of reduced intensity conditioning (RIC) has lowered the TRM associated with myeloablative conditioning,there is no improvement in survival of allo-RIC compared to autologous stem cell transplantation (auto-HSCT).New strategies are discussed with the aim of lowering transplant toxicity and boosting the graft-versus-myeloma effect,and these are urgently needed to make allo-RIC safer and more effective for myeloma patients.In this review,results from studies of allo-HSCT in MM are presented.